364 related articles for article (PubMed ID: 35859731)
21. Dual targeting mesoporous silica nanoparticles for inhibiting tumour cell invasion and metastasis.
Li W; Guo Z; Zheng K; Ma K; Cui C; Wang L; Yuan Y; Tang Y
Int J Pharm; 2017 Dec; 534(1-2):71-80. PubMed ID: 28958879
[TBL] [Abstract][Full Text] [Related]
22. Carboxyl-functionalized mesoporous silica nanoparticles for the controlled delivery of poorly water-soluble non-steroidal anti-inflammatory drugs.
Gou K; Wang Y; Guo X; Wang Y; Bian Y; Zhao H; Guo Y; Pang Y; Xie L; Li S; Li H
Acta Biomater; 2021 Oct; 134():576-592. PubMed ID: 34280558
[TBL] [Abstract][Full Text] [Related]
23. In Situ Synthesis of Ultrathin ZIF-8 Film-Coated MSNs for Codelivering Bcl 2 siRNA and Doxorubicin to Enhance Chemotherapeutic Efficacy in Drug-Resistant Cancer Cells.
Pan QS; Chen TT; Nie CP; Yi JT; Liu C; Hu YL; Chu X
ACS Appl Mater Interfaces; 2018 Oct; 10(39):33070-33077. PubMed ID: 30203954
[TBL] [Abstract][Full Text] [Related]
24. Thermo-responsive mesoporous silica/lipid bilayer hybrid nanoparticles for doxorubicin on-demand delivery and reduced premature release.
Zhang Q; Chen X; Shi H; Dong G; Zhou M; Wang T; Xin H
Colloids Surf B Biointerfaces; 2017 Dec; 160():527-534. PubMed ID: 29024917
[TBL] [Abstract][Full Text] [Related]
25. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
26. Nuclear-Targeting MSNs-Based Drug Delivery System: Global Gene Expression Analysis on the MDR-Overcoming Mechanisms.
Li X; Pan L; Shi J
Adv Healthc Mater; 2015 Dec; 4(17):2641-8. PubMed ID: 26450832
[TBL] [Abstract][Full Text] [Related]
27. PEG-templated mesoporous silica nanoparticles exclusively target cancer cells.
Morelli C; Maris P; Sisci D; Perrotta E; Brunelli E; Perrotta I; Panno ML; Tagarelli A; Versace C; Casula MF; Testa F; Andò S; Nagy JB; Pasqua L
Nanoscale; 2011 Aug; 3(8):3198-207. PubMed ID: 21725561
[TBL] [Abstract][Full Text] [Related]
28. A Review on Recent Technologies and Patents on Silica Nanoparticles for Cancer Treatment and Diagnosis.
Gupta A; Kushwaha SS; Mishra A
Recent Pat Drug Deliv Formul; 2020; 14(2):126-144. PubMed ID: 32928094
[TBL] [Abstract][Full Text] [Related]
29. A surface-grafted ligand functionalization strategy for coordinate binding of doxorubicin at surface of PEGylated mesoporous silica nanoparticles: Toward pH-responsive drug delivery.
Zhang Q; Zhao H; Li D; Liu L; Du S
Colloids Surf B Biointerfaces; 2017 Jan; 149():138-145. PubMed ID: 27750088
[TBL] [Abstract][Full Text] [Related]
30. A Dual Concentration-Tailored Cytokine-Chemo Nanosystem to Alleviate Multidrug Resistance and Redirect Balance of Cancer Proliferation and Apoptosis.
Hsia Y; Sivasubramanian M; Chu CH; Chuang YC; Lai YK; Lo LW
Int J Nanomedicine; 2023; 18():4253-4274. PubMed ID: 37534057
[TBL] [Abstract][Full Text] [Related]
31. Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo.
Lin D; Cheng Q; Jiang Q; Huang Y; Yang Z; Han S; Zhao Y; Guo S; Liang Z; Dong A
Nanoscale; 2013 May; 5(10):4291-301. PubMed ID: 23552843
[TBL] [Abstract][Full Text] [Related]
32. Biodegradable nanocarriers based on chitosan-modified mesoporous silica nanoparticles for delivery of methotrexate for application in breast cancer treatment.
Shakeran Z; Keyhanfar M; Varshosaz J; Sutherland DS
Mater Sci Eng C Mater Biol Appl; 2021 Jan; 118():111526. PubMed ID: 33255079
[TBL] [Abstract][Full Text] [Related]
33. Enzyme-induced and tumor-targeted drug delivery system based on multifunctional mesoporous silica nanoparticles.
Cheng YJ; Luo GF; Zhu JY; Xu XD; Zeng X; Cheng DB; Li YM; Wu Y; Zhang XZ; Zhuo RX; He F
ACS Appl Mater Interfaces; 2015 May; 7(17):9078-87. PubMed ID: 25893819
[TBL] [Abstract][Full Text] [Related]
34. Mesoporous silica nanoparticles for therapeutic/diagnostic applications.
Jafari S; Derakhshankhah H; Alaei L; Fattahi A; Varnamkhasti BS; Saboury AA
Biomed Pharmacother; 2019 Jan; 109():1100-1111. PubMed ID: 30551360
[TBL] [Abstract][Full Text] [Related]
35. Controlled release of silyl ether camptothecin from thiol-ene click chemistry-functionalized mesoporous silica nanoparticles.
Yan Y; Fu J; Wang T; Lu X
Acta Biomater; 2017 Mar; 51():471-478. PubMed ID: 28131940
[TBL] [Abstract][Full Text] [Related]
36. Aptamer-modified chitosan-capped mesoporous silica nanoparticles for co-delivery of cytarabine and daunorubicin in leukemia.
Heydari SR; Ghahremani MH; Atyabi F; Bafkary R; Jaafari MR; Dinarvand R
Int J Pharm; 2023 Nov; 646():123495. PubMed ID: 37806507
[TBL] [Abstract][Full Text] [Related]
37. Mesoporous Silica Nanoparticles-Based Nanoplatforms: Basic Construction, Current State, and Emerging Applications in Anticancer Therapeutics.
Feng Y; Liao Z; Li M; Zhang H; Li T; Qin X; Li S; Wu C; You F; Liao X; Cai L; Yang H; Liu Y
Adv Healthc Mater; 2023 Jun; 12(16):e2201884. PubMed ID: 36529877
[TBL] [Abstract][Full Text] [Related]
38. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
Zhang W; Liu M; Liu A; Zhai G
Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
[TBL] [Abstract][Full Text] [Related]
39. Egg-yolk core-shell mesoporous silica nanoparticles for high doxorubicin loading and delivery to prostate cancer cells.
Tiburcius S; Krishnan K; Jose L; Patel V; Ghosh A; Sathish CI; Weidenhofer J; Yang JH; Verrills NM; Karakoti A; Vinu A
Nanoscale; 2022 May; 14(18):6830-6845. PubMed ID: 35441642
[TBL] [Abstract][Full Text] [Related]
40. Multifunctional mesoporous silica nanoparticles mediated co-delivery of paclitaxel and tetrandrine for overcoming multidrug resistance.
Jia L; Li Z; Shen J; Zheng D; Tian X; Guo H; Chang P
Int J Pharm; 2015 Jul; 489(1-2):318-30. PubMed ID: 25956050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
